Literature DB >> 16251193

Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: potential implications for tumorigenesis.

Vladislav S Golubkov1, Alexei V Chekanov, Stephen J Doxsey, Alex Y Strongin.   

Abstract

Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits distinctive and important pericellular cleavage functions. Recently, we determined that MT1-MMP was trafficked to the centrosomes in the course of endocytosis. Our data suggested that the functionally important, integral, centrosomal protein, pericentrin-2, was a cleavage target of MT1-MMP in human and in canine cells and that the sequence of the cleavage sites were ALRRLLG1156 downward arrow L1157FG and ALRRLLS2068 downward arrow L2069FG, respectively. The presence of Asp-948 at the P1 position inactivated the corresponding site (ALRRLLD948-L949FGD) in murine pericentrin. To confirm that MT1-MMP itself cleaves pericentrin directly, rather than indirectly, we analyzed the cleavage of the peptides that span the MT1-MMP cleavage site. In addition, we analyzed glioma U251 cells, which co-expressed MT1-MMP with the wild type murine pericentrin and the D948G mutant. We determined that the D948G mutant that exhibited the cleavage sequence of human pericentrin was sensitive to MT1-MMP, whereas unmodified murine pericentrin was resistant to proteolysis. Taken together, our results confirm that MT1-MMP cleaves pericentrin-2 in humans but not in mice and that mouse models of cancer probably cannot be used to critically examine MT1-MMP functionality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251193     DOI: 10.1074/jbc.M510139200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  MMPs in unusual places.

Authors:  David M Hockenbery
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 2.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 3.  Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond.

Authors:  Piotr Cieplak; Alex Y Strongin
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-03-24       Impact factor: 4.739

4.  Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.

Authors:  Tyler Lopez; Dong Hyun Nam; Evan Kaihara; Zahid Mustafa; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2017-02-20       Impact factor: 4.530

5.  Evidence for a cooperative role of gelatinase A and membrane type-1 matrix metalloproteinase during Xenopus laevis development.

Authors:  Takashi Hasebe; Rebecca Hartman; Liezhen Fu; Tosikazu Amano; Yun-Bo Shi
Journal:  Mech Dev       Date:  2006-09-10       Impact factor: 1.882

Review 6.  Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development.

Authors:  Lidiya S Orlichenko; Derek C Radisky
Journal:  Clin Exp Metastasis       Date:  2008-02-20       Impact factor: 5.150

7.  Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.

Authors:  Andrei V Chernov; Nor Eddine Sounni; Albert G Remacle; Alex Y Strongin
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

8.  Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis.

Authors:  Jeewon Kim; Yoon-La Choi; Alice Vallentin; Ben S Hunrichs; Marc K Hellerstein; Donna M Peehl; Daria Mochly-Rosen
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 9.  Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.

Authors:  Maria V Barbolina; M Sharon Stack
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

Review 10.  Stromal induction of breast cancer: inflammation and invasion.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.